2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma.
Von Rohr, A
Radford, John A
AffiliationInstitute of Medical Oncology, Inselspital, Berne, Switzerland.
MetadataShow full item record
AbstractPURPOSE: This phase II multi-institutional trial was designed to assess response and toxicity of 2-chlorodeoxyadenosine (2-CDA) in patients with previously untreated follicular lymphoma. The clinical significance of detecting cells carrying the t(14;18) translocation (bcl-2/JH rearrangement) in peripheral blood and bone marrow by polymerase chain reaction (PCR) before, during and after treatment was also examined. PATIENTS AND METHODS: Between May 1993 and October 1995, 37 patients were accrued: male/female: 15/22, median age 51 years (range: 20-78), stage III/IV: 9/28. Patients received a total 2-CDA dose of 0.7 mg/kg as continuous s.c. or i.v. infusions over 7 days, every 28 days for a maximum of 5 cycles. A total of 165 cycles were administered. In 25 patients, blood and bone marrow before, during and after treatment were available for PCR analysis of the bcl-2/JH rearrangements. RESULTS: All 37 patients were evaluable for response and toxicity. The overall response rate was 84% (95% confidence interval, 68%-94%) with 14% CR (n = 5) and 70% PR (n = 26) and a median time to treatment failure of 15.7 months. bcl-2/JH rearrangement in peripheral blood and/or bone marrow was found in 10/25 of patients (40%) before treatment and 5 of these became repeatedly negative after 2-CDA therapy. There was no apparent association between bcl-2/ JH result and response. In 11 patients, 2-CDA was stopped because of progressive disease (n = 4), myelotoxicity (grade 2-3, n = 4), and other causes (n = 3, pulmonary embolism, metabolic disorder, and patient's decision). Four patients (11%) suffered from infections (grade 2-3). In 6 patients, persistent thrombocytopenia of 7.5 months (range: 3-21) occurred after completion of the 5 cycles. CONCLUSION: 2-CDA is active in untreated follicular lymphomas, but time to treatment failure suggests no advantage compared with standard treatment and toxicity on haematopoietic stem cells appears to be more pronounced. Molecular remission is induced in a considerable proportion of patients with disappearance of the bcl-2/JH rearrangement, and its possible significance as a predictive factor for quality of response and relapse warrants further study.
Citation2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. 1996, 7 (8):793-9 Ann Oncol
JournalAnnals of Oncology
- 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
- Authors: Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD
- Issue date: 1992 Mar
- High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
- Authors: Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA
- Issue date: 2001 Nov-Dec
- Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
- Authors: Plosker GL, Figgitt DP
- Issue date: 2003
- Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
- Authors: Piro LD, Carrera CJ, Carson DA, Beutler E
- Issue date: 1990 Apr 19
- Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
- Authors: Rummel MJ, Chow KU, Karakas T, Jäger E, Mezger J, von Grünhagen U, Schalk KP, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS
- Issue date: 2002 Sep